Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Shares Outstanding (Weighted Average) (2016 - 2025)

Voyager Therapeutics' Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $58.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 1.65% year-over-year to $58.8 million; the TTM value through Sep 2025 reached $58.8 million, up 1.65%, while the annual FY2019 figure was $35.9 million, 11.95% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $58.8 million at Voyager Therapeutics, up from $58.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $58.8 million in Q3 2025 and bottomed at $37.5 million in Q1 2021.
  • The 4-year median for Shares Outstanding (Weighted Average) is $57.4 million (2024), against an average of $50.0 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 2.16% in 2025 against a maximum downside of 1.36% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $37.6 million in 2021, then increased by 1.6% to $38.2 million in 2022, then surged by 51.51% to $57.9 million in 2024, then rose by 1.65% to $58.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Shares Outstanding (Weighted Average) are $58.8 million (Q3 2025), $58.5 million (Q2 2025), and $58.3 million (Q1 2025).